Chlamydial Antibiotic Resistance and Treatment Failure in Veterinary and Human Medicine

被引：61
作者：
Borel N. [1 ]
Leonard C. [1 ]
Slade J. [2 ]
Schoborg R.V. [2 ]
机构：
[1] Institute of Veterinary Pathology, Department of Pathobiology, Vetsuisse Faculty, University of Zurich, Winterthurerstrasse 268, Zurich
[2] Department of Biomedical Sciences, Center of Excellence for Inflammation, Infectious Disease and Immunity, Box 70579, Quillen College of Medicine, East Tennessee State University, Box 70579, Johnson City, 37614-0579, TN
来源：
Current Clinical Microbiology Reports | 2016年 / 3卷 / 1期
关键词：
Chlamydia muridarum; Chlamydia suis; Chlamydia trachomatis; Gastrointestinal infection; Tetracycline resistance; Treatment failure;
D O I：
10.1007/s40588-016-0028-4
中图分类号：
学科分类号：
摘要：
The Chlamydiaceae are widespread pathogens of both humans and animals. Chlamydia trachomatis infection causes blinding trachoma and reproductive complications in humans. Chlamydia pneumoniae causes human respiratory tract infections and atypical pneumonia. Chlamydia suis infection is associated with conjunctivitis, diarrhea, and failure to gain weight in domestic swine. Chlamydial infections in humans and domesticated animals are generally controlled by antibiotic treatment—particularly macrolides (usually azithromycin) and tetracyclines (tetracycline and doxycycline). Tetracycline-containing feed has also been used to limit infections and promote growth in livestock populations, although its use has decreased because of growing concerns about antimicrobial resistance development. Because Sandoz and Rockey published an elegant review of chlamydial anti-microbial resistance in 2010, we will review the following: (i) antibiotic resistance in C. suis, (ii) recent evidence for acquired resistance in human chlamydial infections, and (iii) recent non-genetic mechanisms of antibiotic resistance that may contribute to treatment failure. © 2016, The Author(s).
引用
收藏
页码：10 / 18
页数：8
相关论文
共 85 条
[1]  
Bavoil P.M., What’s in a word: the use, misuse, and abuse of the word “persistence” in Chlamydia biology, Front Cell Infect Microbiol, 4, (2014)
[2]  
Wyrick P.B., Chlamydia trachomatis persistence in vitro: an overview, J Infect Dis, 201, pp. 88-95, (2010)
[3]  
Schoborg R.V., Chlamydia persistence—a tool to dissect chlamydia-host interactions, Microbes Infect, 13, pp. 649-662, (2011)
[4]  
Kintner J., Lajoie D., Hall J., Whittimore J., Schoborg R.V., Commonly prescribed β-lactam antibiotics induce C. trachomatis persistence/stress in culture at physiologically relevant concentrations, Front Cell Infect Microbiol, 4, (2014)
[5]  
Phillips Campbell R., Kintner J., Whittimore J., Schoborg R.V., Chlamydia muridarum enters a viable but non-infectious state in amoxicillin-treated BALB/c mice, Microbes Infect, 14, pp. 1177-1185, (2012)
[6]  
Mariotti S.P., Pascolini D., Rose-Nussbaumer J., Trachoma: global magnitude of a preventable cause of blindness, Br J Ophthalmol, 93, pp. 563-568, (2009)
[7]  
Global Incidence and Prevalence of Selected Curable Sexually Transmitted Infections-2008, (2012)
[8]  
Marrazzo J., Suchland R., Recent advances in understanding and managing Chlamydia trachomatis infections, F1000Prime Rep, 6, (2014)
[9]  
Owusu-Edusei K., Chesson H.W., Gift T.L., Tao G., Mahajan R., Ocfemia M.C.B., Et al., The estimated direct medical cost of selected sexually transmitted infections in the United States, 2008, Sex Transm Dis, 40, pp. 197-201, (2013)
[10]  
Al-Younes H.M., High prevalence of Chlamydia pneumoniae infection in an asymptomatic Jordanian population, J Microbiol Immunol Infect, 47, pp. 412-417, (2014)
123456789